molecular weight protein 7) subunits of immunoproteasome, [8] replace the proteasome subunits in ubiquitin-proteasome system as "immune" subunits. [12, 13] The immunoproteasome enhances the degradation of Aβ amyloid in Alzheimer's disease (AD), keep intracellular protein homeostasis as well as provide antigen peptides to TAP. [5, 8] TAP delivers the antigenic peptides from cytoplasm to endoplasmic reticulum by loading on MHC-I molecules. [14] Based on the similar pathogenesis of protein degradation on PD, [15] we hypotheses that PSMB and TAP gene may be involved in the ɑ-synuclein degradation with more genetic susceptibility to PD by the regulation of immunoproteasome in dopaminergic neurons.
To date, the association of single nucleotide polymorphisms (SNPs) in PSMB and TAP genes with PD is not clear yet. In this case-control study, we made a linkage analysis on PD population by choosing 15 SNPs of PSMB and TAP genes which location in coding exons and the average minor allele frequency ≥0.05 [ Figure 1b ]. The 15 SNPs include rs116076690, rs2071543 in PSMB8, rs17587 in PSMB9, rs1135216 in TAP1, rs2228391, rs2228396, rs241447, rs241448, and rs4148876 in TAP2, respectively [ Figure 1a ]. Among them, several SNPs have been proved to be associated with the immune dysregulation. For example, rs2071543 and rs2228396 were found to be associated to rheumatoid arthritis, [16] rs1135216 and rs2228396 associated to leprosy, [17] rs241447 and rs4148876 associated to spondyloarthritis, [18] rs241448 associated to type 1 diabetes, [19, 20] but no information was reported on the association between SNPs of rs17587 and rs116076690 and PD. Thus, using SNPs genotyping analyses, we tried to investigate the PD-susceptible SNPs of PSMB8, PSMB9, TAP1, and TAP2 genes in the Han Chinese population.
Methods

Study population
Subjects included 542 sporadic PD patients and 674 healthy controls, which were recruited from PD Research Center and Healthcare Center of the First Affiliated Hospital of Sun Yat-Sen University since 2009-2014. All patients were diagnosed by the United Kingdom Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria for PD. [21] The mean age of PD patients was 59.6 ± 17.2 years, of which 320 were male and 222 were female. The mean age of healthy controls was 55.4 ± 12.5 years, of which 462 volunteers were male and 212 volunteers were female. Informed consent was obtained from all subjects who specified self-claimed membership in the Han ethnic population, residency in the Guangdong Province of China with no family migration of four generations. This study followed the ethnic guidelines and was approved by the hospital ethnic committee.
DNA collections and single nucleotide polymorphism genotyping
Venous blood samples (5 ml) were collected from all subjects. DNA was extracted by TRIZOL method (Life Technologies Inc., Grand Island, NY, USA). The reference genomic DNA sequences were obtained from the Genebank database (http:// www.ncbi.nlm.nih.gov/Genbank/). Primers for SNPs in PSMB and TAP were designed using the Primer Premier V5.0 software (Premier Biosoft International Inc., Palo Alto, CA, USA), then synthesized by Invitrogen (Thermo Fisher Scientific Inc., Waltham, MA, USA). The SNaPshot genotyping (Applied Biosystems Co., Foster City, CA, USA) of rs116076690, rs2071543 in PSMB8, rs17587 in PSMB9, rs1135216 in TAP1, and rs2228391, rs2228396, rs241447, rs241448, and rs4148876 in TAP2 were shown in Supplement Table 1 . Capillary electrophoresis was conducted through ABI 3730XL DNA Analyzer (Applied Biosystems Co., Foster City, CA, USA). DNA sequences were analyzed by Mutation Surveyor v2.2 software (SoftGenetics Inc. LLC, State College, PA, USA) and GeneMapper 4.1 software (Applied Biosystems Co., Foster City, CA, USA). [22, 23] 
Statistical analysis
All the groups were tested for deviation from HardyWeinberg equilibrium (HWE) by statistical software SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA). The haplotype analysis was performed by Arlequin 3.5 software program (http://cmpg.unibe.ch/software/arlequin3). The power analysis was calculated to predict the sample size of patient and control groups or evaluate the test by Power and Sample Size Calculation software version 3.0 (http:// biostat.mc.vanderbilt.edu/, Vanderbilt University, TN, USA). 
Results
SNaPshot analysis on PSMB8, PSMB9, TAP1, and TAP2
Healthy controls were subjected to HWE for rs116076690, rs2071543 in PSMB8, rs17587 in PSMB9, rs1135216 in TAP1, and rs2228391, rs2228396, rs241447, rs241448, and rs4148876 in TAP2 (df = 1, P > 0.05). The standardized measure of linkage disequilibrium (LD) was calculated for all identified SNPs on the patients and controls. There was only one significant LD value between rs241448 and rs241447 in TAP2 in both patients and controls [D > 0.8 and r 2 > 0.8, Figure 1b ]. The power analysis suggested that the sample size was enough for the susceptibility analysis under the conditions: relative risk (odds ratio [OR]) ≥1.5, disorder related gene frequency = 0.30, α = 0.05 and 1− β = 80%. There was no significant difference in genotype or allele frequency between PD patients and healthy controls at all SNPs [ Table 1 ]. The haplotype analysis was performed with the SNPs across PSMB8, PSMB9, TAP1, and TAP2 genes. The PSMB9-TAP1-PSMB8-TAP2 haplotype (AA-G-C-AGATC) showed an obvious difference in PD group compared with control group (33.5% vs. 39%; P < 0.049), but the difference lost significance after the Bonferroni correction (corrected P > 0.05).
Stratified association analysis for rs17587
The sequence result of rs17587 locus was presented in Figure 2 . It showed that no significant association was found between genotype frequencies of rs17587 and PD [ Table 1 ]. After stratified analysis based on gender, the frequencies of rs17587 polymorphism were still distributed in HWE. We observed a significant association in females, but nonsignificant association in males. The Breslow-Day test for heterogeneous association between males and females was significant (P = 0.013). Base on the dominant model, the female PD population showed a significant (P = 0.002) lower odds of A/A + A/G to GG compared with female controls, with OR = 0.535 (95% confidence interval = 0.358-0.798), after age adjustment [ Table 2 ]. Furthermore, stratified analysis on age of disease onset did not show any significant difference between PD patients and healthy controls.
dIscussIon
The main finding of this study was that only rs17587-G/G at PSMB9 may increase a risk of PD for Chinese female besides other identified SNPs variants in PSMB8, PSMB9, TAP1, and TAP2 genes. PSMB9 containing rs17587 at exon 4 encodes the immunoproteasome β1 subunit possessing glutamyl peptide hydrolyzing activity in protein degradation and participates in the immune response to MHC Class I molecules. [24] It was reported that AD patients carrying the G/G of rs17587 presented a higher immunoproteasome activity in the brain than that carrying G/A. [25] The immunoproteasome failed to promote protein degradation in PSMB9 knockout mice. [26, 27] Similarly, α-synuclein accumulation accompanying microglial inflammation was found in PD with MHC-II expression, although their relationship between PSMB9 and PD is still unclear. [2] Here, we found that PD female patients carried a higher frequency of rs17587-G/G versus (A/A + G/A), suggesting rs17587-G/G may be a potential risk loci for female PD. It is worth noting that the female PD patients are usually older more than 50 years and accompanied a decreased estrogen level in menopause. [28] Thus, we inferred that estrogen may be involved in the regulation of PSMB9 in female PD patients. It was reported that estrogen suppresses microglia and astrocyte activation and modulate the inflammation process by inhibiting the MHC pathways in central nervous system, play a role in the anti-inflammatory to prevent lipopolysaccharide-induced inflammatory mediators released by microglia and also promotes the degradation of aggregated protein. [29, 30] For example, the menopausal women face an increased risk of AD, which is closely related with cleaning of amyloid-β peptides aggregates. [31, 32] Estrogen plays a role in the improvement of motor bradykinesia in postmenopausal women in a randomized pilot trial of PD. [33] It is interest that the G → A substitution of rs17587 in exon 4 of PSMB9 may lead to alteration of arginine to histidine, potentially affecting the immunoproteasome activity. [25, 34] Due to the female menopausal PD cases carrying higher frequency of rs17587-G/G, we here inferred that PSMB9 and estrogen may play an important role on PD development under the modification of immunoproteasome and protein degradation.
PSMB8 encodes β2 subunit of immunoproteasome and shares a similar mechanism on the protein degradation and immune response like PSMB9. [35] Mutation of PSMB8 was reported to be closely related to lipodystrophy and autoinflammatory disorder. [36] In our study, we found no significant differences of rs116076690 and rs2071543 polymorphisms in PSMB8 between PD and controls. A larger sample for further investigation on PSMB8 could help to disclose the right relationship with PD.
TAP1 and TAP2 belong to an ATP-binding cassette family, transporting small antigenic peptides into the lumen of the endoplasmic reticulum. [5] In TAP knockout cells, the antigenic peptides were not effectively transported into the endoplasmic reticulum to abolish endogenous antigen presentation. [37, 38] Bullido et al. reported that rs241448 in TAP2 is associated with AD.
[39] However, we found no significant differences in TAP polymorphisms between PD patients and healthy controls in the Han Chinese population after screening for the genotype and allele distribution of rs1135216, rs4148876, rs2228391, rs2228396, rs241447, and rs241448 in TAP1 and TAP2. Stratified analysis based on gender or onset age did not reveal any significant variation between PD patients and control.
The PSMB8, PSMB9, TAP1, and TAP2 genes at chromosome 6 are located at an adjacent range from 32.859 Mb and 32.821 Mb and involved in the protein degradation and antigen presentation, [40] suggesting a possible LD of the above SNPs with PD patients. However, our result showed that a significant LD value was only calculated for rs241448 and rs241447 in TAP2, but no significant linkage to PD patients under the TAP2 haplotypic analysis. The PSMB9-TAP1-PSMB8-TAP2 haplotype (AA-G-C-AGATC) was also found to be a slight association with PD, but no significance after the Bonferroni correction. In conclusion, we found that Chinese females carrying rs17587-G/G of PSMB9 may increase a risk for developing PD, but other SNPs and their haplotypes seem no risk effect on PD.
Further investigation recruited more patients may need to uncover any association between SNPs in HLA Class II with PD population to explore its immune dysfunction on the pathogenesis of PD.
In summary, we evaluated the association of SNPs in PSMB and TAP with PD and found: (i) no linkage was revealed between SNPs at PSMB8, TAP1, and TAP2 and PD (ii) the rs17587-G at PSMB9 may develop an increased risk of PD for Chinese female population. 
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.
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